Status:
COMPLETED
Effects of Pioglitazone in Congenital Adrenal Hyperplasia
Lead Sponsor:
Radboud University Medical Center
Conditions:
Congenital Adrenal Hyperplasia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Congenital adrenal hyperplasia, an autosomal recessive condition, is mainly caused by mutations in the gene 21-hydroxylase and is treated with glucocorticoids in a slightly supraphysiological dose. Ad...
Eligibility Criteria
Inclusion
- biochemical and genetically proven congenital adrenal hyperplasia
- stable corticosteroid replacement for 3 months
Exclusion
- age \< 18 years
- inability to give informed consent
- significant cardiovascular disease, defined as myocardial infarction or stroke, six months preceding the study
- significant renal disease, GFR \< 30 ml/min
- significant liver disease, defined as more than 3 times upper limit of normal values of alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
- pregnancy
- mental disease
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00151710
Last Update
March 1 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud University Nijmegen Medical Centre
Nijmegen, Gelderland, Netherlands, 6500 HB